Potential use of bacteriophages in modern infectiology;Potentialités des bactériophages pour l'infectiologie moderne

Revue de Medecine Interne

Volumn 37, Issue 10, 2016, Pages 657-660

  Prevel, R ^a   Dufour, N ^b,c,d  

^a HÔPITAL PELLEGRIN   (France)

^b HÔPITAL LOUIS MOURIER   (France)

^c INSERM   (France)

^d INSTITUT PASTEUR   (France)

Author keywords

Antibiotic resistance; Bacteriophage; Phage therapy; Targeted therapy

Indexed keywords

ARTICLE; BACTERIOPHAGE; ESCHERICHIA COLI; KLEBSIELLA PNEUMONIAE; ANTIBIOTIC RESISTANCE; BACTERIAL INFECTIONS; BIOMEDICAL ENGINEERING; HUMAN; MOLECULARLY TARGETED THERAPY; MULTIDRUG RESISTANCE; PHYSIOLOGY; PROCEDURES; TRENDS;

BACTERIAL INFECTIONS; BACTERIOPHAGES; BIOMEDICAL ENGINEERING; DRUG RESISTANCE, MICROBIAL; DRUG RESISTANCE, MULTIPLE, BACTERIAL; HUMANS; MOLECULAR TARGETED THERAPY;

EID: 84973894664     PISSN: 02488663     EISSN: 17683122     Source Type: Journal    
DOI: 10.1016/j.revmed.2016.05.002     Document Type: Article

References (17)

1. [1] Arnaud, I., Jarlier, V., groupe de travail BMR-RAISIN. Surveillance des bactéries multirésistantes dans les établissements de santé en France. Réseau BMR-RAISIN, résultats 2013. 2015, Institut national de veille sanitaire.
2. [2] Colomb-Cotinat, M., Lacoste, J., Coignard, B., Vaux, S., Brun-Buisson, C., Jarlier, V., Morbidité et mortalité des infections à bactéries multi-résistantes aux antibiotiques en France en 2012. Étude Burden BMR, INVS. 2015, Institut National de Veille Sanitaire, Saint-Maurice [21 p.].
3. [3] Center for Disease Control. Antibiotic resistance threats in the United States. 2013 [http://www.cdc.gov/drugresistance/threat-report-2013. Page accessed on March, 2014].
4. [4] Carlet, J., Le Coz, P., Rapport du groupe de travail spécial pour la préservation des antibiotiques. 2015, Ministère des Affaires Sociales, de la Santé et des Droits des Femmes.
5. [5] Nobrega, F.L., Costa, A.R., Kluskens, L.D., Azeredo, J., Revisiting phage therapy: new applications for old resources. Trends Microbiol 23 (2015), 185–191.
6. [6] Rohwer, F., Global phage diversity. Cell, 113, 2003, 141.
7. [7] Wommack, K.E., Colwell, R.R., Virioplankton: viruses in aquatic ecosystems. Microbiol Mol Biol Rev 64 (2000), 69–114.
8. [8] Pires, D.P., Oliveira, H., Melo, L.D., Sillankorva, S., Azeredo, J., Bacteriophage-encoded depolymerases: their diversity and biotechnological applications. Appl Microbiol Biotechnol 100 (2016), 2141–2151.
9. [9] Abedon, S.T., Kuhl, S.J., Blasdel, B.G., Kutter, E.M., Phage treatment of human infections. Bacteriophage 1 (2011), 66–85.
10. [10] Wright, A., Hawkins, C.H., Anggard, E.E., Harper, D.R., A controlled clinical trial of a therapeutic bacteriophage preparation in chronic otitis due to antibiotic-resistant Pseudomonas aeruginosa; a preliminary report of efficacy. Clin Otolaryngol 34 (2009), 349–357.
11. [11] Sarker, S.A., Sultana, S., Reuteler, G., Moine, D., Descombes, P., Charton, F., et al. Oral Phage therapy of acute bacterial diarrhea with two coliphage preparations: a randomized trial in children from Bangladesh. EBioMedicine 4 (2016), 124–137.
12. [12] Speck, P., Smithyman, A., Safety and efficacy of phage therapy via the intravenous route. FEMS Microbiol Lett, 363(3), 2016, 10.1093/femsle/fnv242.
13. [13] Comeau, A.M., Tetart, F., Trojet, S.N., Prere, M.F., Krisch, H.M., Phage-Antibiotic Synergy (PAS): beta-lactam and quinolone antibiotics stimulate virulent phage growth. PLoS One, 2, 2007, e799.
14. [14] Debarbieux, L., Pirnay, J.P., Verbeken, G., De Vos, D., Merabishvili, M., Huys, I., et al. A bacteriophage journey at the European Medicines Agency. FEMS Microbiol Lett, 363(2), 2016, 10.1093/femsle/fnv225.
15. [15] EuroCD.C., European Centre for Disease Prevention and Control - Antimicrobial resistance interactive database (EARS-Net). 2014 [http://ecdc.europa.eu/en/healthtopics/antimicrobial_resistance/database/Pages/graph_reports.aspx. Page accessed on February, 2016].
16. [16] Hasman, H., Hammerum, A.M., Hansen, F., Hendriksen, R.S., Olesen, B., Agerso, Y., et al. Detection of mcr-1 encoding plasmid-mediated colistin-resistant Escherichia coli isolates from human bloodstream infection and imported chicken meat, Denmark, 2015. Euro Surveill, 2015, 20.
17. [17] Liu, Y.Y., Wang, Y., Walsh, T.R., Yi, L.X., Zhang, R., Spencer, J., et al. Emergence of plasmid-mediated colistin resistance mechanism MCR-1 in animals and human beings in China: a microbiological and molecular biological study. Lancet Infect Dis 16 (2016), 161–168.